Keywords: Catamenial epilepsy, Levetiracetam, Intermittent treatment.
Catamenial epilepsy, first reported in 1881,1 is commonly defined as a periodic increase in seizure frequency in women with epilepsy during menstruation, or at any specific point in the menstrual cycle.2 Studies have reported the prevalence of catamenial epilepsy in epileptic patients to be 31-60%.3-5 In other words, at least 1 in 3 women with epilepsy develops this condition.
Cavazos failed to note that the treatment for catamenial epilepsy might by danazol to suppress the cycle.
NEWS, there have been no large prospective treatment studies in women with catamenial epilepsy and there is no universally accepted therapy.
To date, there have been no large prospective treatment studies in women with catamenial epilepsy. Reported therapeutic successes are strictly anecdotal, and there is no universally accepted therapy, the neurologist added.
The biologic basis of catamenial epilepsy is grounded in two well-established observations: Estrogens are mildly proconvulsant, whereas progesterones have a slight anticonvulsant effect.
Abstract: The prevalence of catamenial epilepsy has been difficult to determine for several reasons, including menstrual cycle variability and randomness of seizure occurrence, a high prevalence of seizure clustering in males and nonmenstruating females with epilepsy, and the lack of a definition of catamenial epilepsy in previous studies.
A pattern of predominant seizure occurrence or exacerbation of seizure frequency in temporal relationship to the menstrual cycle is referred to as catamenial epilepsy. Catamenial epilepsy was first examined by Gowers in 1885 (as cited in Newmark and Penry) and Locock in 1857 (as cited in Bandler, Kaufman, Dykens, Schleifer and Shapiro).
[12.] Laidaw J: Catamenial epilepsy
. Lancet 1956:271:1235-1237.